Edition:
United Kingdom

Therapix Biosciences Ltd (TRPX.OQ)

TRPX.OQ on NASDAQ Stock Exchange Capital Market

4.96USD
11 Dec 2018
Change (% chg)

-- (--)
Prev Close
$4.96
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
44,535
52-wk High
$9.29
52-wk Low
$3.07

Latest Key Developments (Source: Significant Developments)

Therapix Biosciences Q3 Loss Per Share $0.50
Monday, 3 Dec 2018 

Therapix Biosciences Ltd ::THERAPIX BIOSCIENCES REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q3 LOSS PER SHARE $0.50.CASH TOTALED $2 MILLION AS OF SEPT 30, 2018, COMPARED TO $9.2 MILLION AS OF DEC 31, 2017.THERAPIX BIOSCIENCES - ANTICIPATES FIRST PATIENT ENROLLMENT FOR PHASE IIB, PLACEBO-CONTROLLED 12-WEEK CLINICAL TRIAL FOR THX-110 IN TS AT H1 2019.THERAPIX BIOSCIENCES - TOP LINE RESULTS FOR PLACEBO-CONTROLLED 12-WEEK CLINICAL TRIAL FOR THX-110 IN TS ARE EXPECTED IN H2 OF 2020.THERAPIX BIOSCIENCES - TOP LINE RESULTS FOR PHASE IIA TRIAL FOR TREATMENT OF OSA ARE EXPECTED IN H1 OF 2019.  Full Article

Therapix Biosciences Reports Qtrly Loss Per ADS of $0.50
Monday, 3 Dec 2018 

Dec 3 (Reuters) - Therapix Biosciences Ltd ::THERAPIX BIOSCIENCES REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q3 LOSS PER ADS $0.50.CASH TOTALED $2 MILLION AS OF SEPT 30, 2018, COMPARED TO $9.2 MILLION AS OF DEC 31, 2017.THERAPIX BIOSCIENCES - ANTICIPATES FIRST PATIENT ENROLLMENT FOR PHASE IIB, PLACEBO-CONTROLLED 12-WEEK CLINICAL TRIAL FOR THX-110 IN TS AT H1 2019.THERAPIX BIOSCIENCES - TOP LINE RESULTS FOR PLACEBO-CONTROLLED 12-WEEK CLINICAL TRIAL FOR THX-110 IN TS ARE EXPECTED IN H2 OF 2020.THERAPIX BIOSCIENCES - TOP LINE RESULTS FOR PHASE IIA TRIAL FOR TREATMENT OF OSA ARE EXPECTED IN H1 OF 2019.  Full Article

Therapix Biosciences Issues $1.5 Million Convertible Debenture
Tuesday, 27 Nov 2018 

Nov 27 (Reuters) - Therapix Biosciences Ltd ::THERAPIX BIOSCIENCES ISSUES $1.5 MILLION CONVERTIBLE DEBENTURE.THERAPIX BIOSCIENCES LTD - SECURITIES PURCHASE AGREEMENT WITH YA II PN LTD FOR UP TO $2.5 MILLION IN PRINCIPAL AMOUNT OF UNSECURED CONVERTIBLE DEBENTURES.THERAPIX BIOSCIENCES LTD - INTENDS TO USE THE PROCEEDS OF THE ISSUANCE OF THE DEBENTURES TO CONTINUE ITS PIPELINE DEVELOPMENT PROGRAMS.  Full Article

FSD Pharma Signs Binding LOI To Acquire Therapix Biosciences
Monday, 22 Oct 2018 

Oct 22 (Reuters) - FSD Pharma Inc ::FSD PHARMA SIGNS BINDING LOI TO ACQUIRE THERAPIX BIOSCIENCES, A NASDAQ TRADED PHARMACEUTICAL COMPANY FOCUSING ON THE DEVELOPMENT OF CANNABINOID-BASED TREATMENTS, TO CREATE MEDICAL CANNABIS INDUSTRY INNOVATOR.FSD PHARMA INC - THERAPIX BIOSCIENCES SHAREHOLDERS WILL RECEIVE $48 MILLION OF FSD STOCK UPON CLOSING OF TRANSACTION.FSD PHARMA INC - TRANSACTION IS ARMS' LENGTH AND NO FINDERS FEES HAVE BEEN PAID.FSD PHARMA INC - ANTICIPATED THAT COMMON SHARES OF COMPANY WILL CONTINUE TO BE LISTED ON CSE AND FRA.FSD PHARMA INC - TERMS OF LOI WILL BE SUPERSEDED BY A DEFINITIVE AGREEMENT, WHICH FSD PHARMA AND THERAPIX INTEND TO EXECUTE WITHIN 30 DAYS.FSD PHARMA INC - INTENDS TO APPLY TO LIST ON NASDAQ.  Full Article

Therapix Announces Positive Data From Pre-Clinical Studies For Pain Treatment Drug
Tuesday, 17 Jul 2018 

July 17 (Reuters) - Therapix Biosciences Ltd ::THERAPIX BIOSCIENCES ANNOUNCES POSITIVE DATA FROM RECENT PRE-CLINICAL STUDIES FOR ITS DRUG CANDIDATE THX-160 FOR TREATMENT OF PAIN.THERAPIX BIOSCIENCES LTD - IN PRECLINICAL STUDIES, THX-160 WAS WELL TOLERATED AND DID NOT CAUSE ANY SIGNIFICANT ADVERSE CLINICAL EFFECTS.THERAPIX BIOSCIENCES - EFFICACY STUDIES SHOWED ANALGESIC SUPERIORITY OF THX-160 OVER CONTROL, WERE COMPARABLE TO HIGH-DOSE MORPHINE ANALGESIC EFFECTS.  Full Article

Therapix Biosciences Signs Term Sheet For The Transfer Of Non-Pain Cannabinoid-Based Drug Pipeline Assets To Cure Pharmaceutical
Thursday, 12 Jul 2018 

July 12 (Reuters) - Therapix Biosciences Ltd ::THERAPIX BIOSCIENCES SIGNS TERM SHEET FOR THE TRANSFER OF NON-PAIN CANNABINOID-BASED DRUG PIPELINE ASSETS TO CURE PHARMACEUTICAL.THERAPIX BIOSCIENCES LTD - PARTIES PROPOSE THAT THERAPIX WILL RECEIVE NEWLY ISSUED SHARES IN CURE IN EXCHANGE FOR ASSETS.THERAPIX BIOSCIENCES - PURSUANT TO TERM SHEET THERAPIX WILL BECOME SIGNIFICANT SHAREHOLDER IN CURE.THERAPIX BIOSCIENCES LTD - TERM SHEET CONTEMPLATES THERAPIX CEO & CHAIRMAN, ASCHER SCHMULEWITZ, WILL BE APPOINTED TO CURE'S BOARD.THERAPIX BIOSCIENCES LTD - RECEIPT OF ADDITIONAL FINANCING IS ONE OF CONDITIONS OF ACQUISITION, SOME OF WHICH MAY BE PROVIDED BY THERAPIX.  Full Article

Therapix Biosciences Ltd Files For Mixed Shelf Of Up To $50 Million
Wednesday, 20 Jun 2018 

June 20 (Reuters) - Therapix Biosciences Ltd ::THERAPIX BIOSCIENCES LTD FILES FOR MIXED SHELF OF UP TO $50 MILLION – SEC FILING.  Full Article

Therapix Biosciences Reports Q1 Shr Loss $0.01
Thursday, 31 May 2018 

May 31 (Reuters) - Therapix Biosciences Ltd ::THERAPIX BIOSCIENCES REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q1 LOSS PER SHARE $0.01.THERAPIX BIOSCIENCES - CASH TOTALED $7.5 MILLION AS OF MARCH 31, 2018, COMPARED TO $9.2 MILLION AS OF DECEMBER 31, 2017.THERAPIX BIOSCIENCES - CO CURRENTLY BELIEVES THAT CASH BALANCE WILL BE SUFFICIENT TO MAINTAIN ITS CURRENT OPERATIONS INTO Q2 2019.  Full Article

Therapix Biosciences Says U.S. FDA Cleared IND For THX-110 In Treatment Of Chronic Low Back Pain
Tuesday, 20 Mar 2018 

March 20 (Reuters) - Therapix Biosciences Ltd ::THERAPIX BIOSCIENCES - U.S. FDA CLEARED IND FOR THX-110 IN TREATMENT OF CHRONIC LOW BACK PAIN.THERAPIX BIOSCIENCES - EXPECTS TO COMMENCE PHASE IIA CLINICAL TRIAL FOR CHRONIC LOW BACK PAIN DRUG DURING Q2 2018.  Full Article

Therapix Biosciences Announces Expansion Into Precision Medicine Through New Fully-Owned Subsidiary
Tuesday, 9 Jan 2018 

Jan 9 (Reuters) - Therapix Biosciences Ltd ::THERAPIX BIOSCIENCES ANNOUNCES EXPANSION INTO PRECISION MEDICINE THROUGH NEW FULLY-OWNED SUBSIDIARY AND PROVIDES CORPORATE UPDATE TODAY AT THE BIOTECH SHOWCASE™ 2018.THERAPIX BIOSCIENCES LTD - ‍EXPANDING INTO PRECISION MEDICINE THROUGH A NEW FULLY-OWNED SUBSIDIARY IN ORDER TO DEVELOP "NOVEL SOLUTIONS FOR PAIN"​.  Full Article

Deals of the day-Mergers and acquisitions

Oct 23 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Tuesday:

No consensus analysis data available.